#
最新临床研究进展，最热临床研究方向
#
ILCA 2023
4项大会口头报告
SIRT联合纳武利尤单抗治疗期间，肝细胞癌患者的外周血T细胞受体库的多样化与其临床获益相关
O-13 Diversification of peripheral blood T cell receptor repertoire during treatment with SIRT plus Nivolumab is associated with clinical benefit in patients with hepatocellular carcinoma.
报告人：Enrique Conde-Gallastegi
O-14 Efficacy and safety analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study.
报告人：Masatoshi Kudo
O-15 Targeted therapy adapted to tumor biology in patients with advanced hepatocellular carcinoma or hepatocholangiocarcinoma refractory to atezolizumab/bevacizumab.
报告人：Wendy Limousin
新辅助免疫疗法在可切除肝细胞癌中的应答预测因素：PRIME-HCC研究初步临床和转化分析
报告人：Antonio D'Alessio
9项获奖优秀壁报
报告人：Tim Meyer
P-12 Transcriptomic analysis reveals non-immune tumor microenvironment features associated with clinical benefit in patients with hepatocellular carcinoma treated with SIRT plus nivolumab
报告人：Enrique Conde-Gallastegi
P-13 Financial and psychological burden of HCC surveillance in patients with cirrhosis
报告人：Manasa Narasimman
P-14 Achievement of cancer and drug-free status by atezolizumab plus bevacizumab followed by curative conversion in patients with TACEunsuitable, intermediate-stage HCC: a multicenter proof-of-concept Study
报告人：Masatoshi Kudo
P-15 VETC (vessel that encapsulate tumor cluster) evaluated in liver biopsy predicts anti-angiogenic benefit in advanced HCC
报告人：Camilla De Carlo
P-16 Integrative analysis of genomic and proteomic data of hepatocellular carcinoma reveals consensus subtypes associated with clinical outcomes and therapeutic targets
报告人：Ju-Seog Lee
P-17 Association with body mass index and risk of hepatocellular carcinoma according to liver disorder status
报告人：Baek Gyu Jun
P-19 Drug-eluting beads vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a randomized clinical trial
报告人：Tan-Yang Zhou
针对肝超声显像不理想的肝癌患者采用非增强造影MRI监测的前瞻性研究
P-20 Prospective study of surveillance non-contrast abbreviated mri for hepatocellular cancer in patients with suboptimal hepatic visualisation on ultrasound
报告人：Mathew Vithayathil
声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。
（来源：《国际肝病》编辑部）